Invivyd Inc.
About
Invivyd is a biotechnology company developing antibody-based medicines for serious infectious diseases, with a mission to rapidly and continually deliver therapies that keep pace with evolving viral threats. Its argument is that vaccines can only go so far, and that antibodies are the natural next step. The company says its medicines are designed to be more potent and more resistant to virus evolution than the human immune system.
To create them, Invivyd uses a proprietary, integrated technology platform to assess, monitor, develop and adapt antibodies. Its pipeline of monoclonal antibody candidates targets prevention or treatment of serious viral diseases, starting with COVID-19 and other high-need indications. A candidate called VYD2311 produced positive topline results in the LIBERTY Phase 3 study, which compared its safety and tolerability with an mRNA-based COVID-19 vaccine, and the company has announced plans for regulatory submission.
What to Know
- The company’s headquarters are in New Haven, Connecticut.
- It runs a dedicated medical information line and a separate channel for reporting adverse events.
- Its stated focus is protecting the most vulnerable people from current and future viral threats.
- Invivyd is listed on the Nasdaq.
- It is a member of the Charles River Regional Chamber.
Is this your business?
Claim it to add hours, photos, a description and a spotlight story.